Mehmet ÖZDEN, Ahmet GÖDEKMERDAN, Nafiye Fulya İLHAN, Emin Tamer ELKIRAN, Hatice Handan AKBULUT

Investigation of hepatocyte growth factor and proinflammatory cytokine levels in patients with febrile neutropenia

It has been thought that hepatocyte growth factor (HGF) levels increase during acute phases of infectious diseases. The aim of this study was to determine whether HGF, C-reactive protein (CRP), and proinflammatory cytokines have any diagnostic and prognostic value, and to assess HGF as a biomarker in patients with febrile neutropenia. Materials and methods: This study included 20 patients with febrile neutropenia as the study group and 20 healthy individuals as the control group. Serial measurements of serum HGF, CRP, and proinflammatory cytokine levels were performed by enzyme-linked immunosorbent assay (ELISA) at the baseline, after 48 h of treatment, and at posttreatment. Results: It was found that HGF levels at the baseline were significantly higher than those in the healthy controls (P = 0.001). It was also seen that HGF levels 48 h after treatment and at posttreatment were significantly lower than those at the baseline (P = 0.012). High-risk group patients had higher mean serum HGF levels compared with the low-risk group. It was detected that IL-6 and TNF-a levels at the baseline were significantly decreased after treatment (P = 0.02 and P = 0.005). Conclusion: Our findings suggested that serial measurement of serum HGF levels may be an important marker to identify risk levels of febrile neutropenia and to predict its prognosis.

Anahtar Kelimeler:

Key words: Febrile neutropenia, hepatocyte growth factor, CRP, cytokine

Investigation of hepatocyte growth factor and proinflammatory cytokine levels in patients with febrile neutropenia

Keywords:

Key words: Febrile neutropenia, hepatocyte growth factor, CRP, cytokine,

PDF

___

Chanock SJ, Pizzo MD. Fever in the neutropenic host. Infectious Diseases Emergencies. Infect Dis Clin North Am 1996; 10: 777–96. 2. Pizzo PA. Fever in immunosuppressed patients. N Engl J Med 1999; 341: 893–900.
Febril Nötropenik Hastalarda Tanı ve Tedavi Kılavuzu. Febril Nötropeni Çalışma Grubu. Flora 2004; 9: 5–28. (In Turkish).
Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, Takahashi K et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988; 81: 414–9. 9. Boros P, Miller CM. Hepatocyte growth factor; a multifunctional cytokine. Lancet 1995; 345: 293–5.
Dudek K, Koziak K, Placha G, Kornasiewicz O, Zieniewicz K, Zurakowski J et al. Early expression of hepatocyte growth factor, interleukin-6, and transforming growth factor-beta 1 and -beta 2 in symptomatic infection in patients who have undergone liver transplantation. Transplant Proc 2009; 41: 240–5.
Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID et al. Scatterfactor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997; 76: 565–77.
Motoki T, Takami Y, Yagi Y, Tai A, Yamamoto I, Gohda E. Inhibition of hepatocyte growth factor induction in human dermal fibroblasts by tryptanthrin. Biol Pharm Bull 2005; 28: 260–6.
Hou XZ, Liu W, Fan HT, Liu B, Pang B, Xin T et al. Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol 2010; 12: 799–803.
Nayeri F, Brudin L, Darelid J, Nilsson I, Fryden A, Söderström C et al. Hepatocyte growth factor may act as an early therapeutic predictor in pneumonia. Scand J Infect Dis 2002; 34: 500–4.
Abednazari H, Xu J, Millinger E, Brudin L, Forsberg P, Nayeri F. Hepatocyte growth factor is a better indicator of therapeutic response than C-reactive protein with in the first day of treatment in pneumonia. Chemotherapy 2006; 52: 260–3.
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038–51.
Bayram I, Erbey F, Alabaz D, Yılmaz S, Tanyeli A. Cefoperazone-sulbactam plus amikacin empirical therapy for febrile neutropenia in children with cancer. Turk J Med Sci 2009; 39: 635–40.
Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005; 103: 2629–35.
Morres KG. Safe and effective outpatient treatment of adults with chemotherapy-induced febrile neutropenia. Am J Health Syst Pharm 2007; 64: 712–7.
Ozden M, Kalkan A, Demirdag K, Kilic SS, Denk A, Yuce P. Hepatocyte growth factor (HGF) in patients with acute brucellosis. Scand J Infect Dis 2004; 36: 109–13.
Ozden M, Kalkan A, Demirdag K, Denk A, Kiliç SS. Hepatocyte growth factor (HGF) in patients with hepatitis B and meningitis. J Infect 2004; 49: 229–5.
Hjorth-Hansen H, Seidel C, Lamvik J, Börset M, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur J Haematol 1999; 62: 129–34.
Ueda T, Takeyama Y, Hori Y, Nishikawa J, Yamamoto M, Saitoh Y. Hepatocyte growth factor in assessment of acute pancreatitis: comparison with C-reactive protein and interleukin-6. J Gastroenterol 1997; 32: 63–70.
Neuenschwander LC, Bittencourt H, Ribeiro AF, Teixeira AL, Teixeira MM, Teixeira JC et al. Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients. Clinics 2011; 66: 1699–705.
Banacloche JG. Biomarkers in fever and neutropenia: A solution in search of a problem? Crit Care Med 2011; 39: 1205– 6.
von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539–44.
Bilgir O, Bilgir F, Kebapcilar L, Bozkaya G, Çalan M, Kırbıyık H et al. Comparative levels of macrophage migration inhibitory factor, procalcitonin, osteoprotegerin, interleukin-8, hs-C reactive protein, D-dimer in febrile neutropenia, newly diagnosed cancer patients, and infectious fever. Transfusion and Apheresis Science 2012; 46: 19–24.
Demir NA, Ural O. Serum interleukin-8 levels may predict relapse in brucellosis. Turk J Med Sci 2012; 42: 796–801.
Tromp YH, Daenen Simon MGJ, Sluiter WJ, Vellenga E. The predictive value of interleukin-8 (IL-8) in hospitalised patients with fever and chemotherapy-induced neutropenia. Eur J Cancer 2009; 45: 596–600.
Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: Review of the literature. Infection 2008; 36: 396–407.